Can-Fite BioPharma Ltd.

Can-Fite BioPharma Ltd. is an Israeli clinical-stage biopharmaceutical company focused on developing orally bioavailable small molecule therapeutic products. The company's core mission is to address significant unmet medical needs in multi-billion dollar markets, primarily in the treatment of cancer, liver, and inflammatory diseases. Its headquarters are located in Petah-Tikva, Israel.

The company's pipeline features proprietary drug candidates that target the Gi protein associated A3 adenosine receptor (A3AR). Key product candidates include Piclidenoson (CF101), which is in a pivotal Phase III clinical study for psoriasis, and Namodenoson (CF102), currently in a pivotal Phase III trial for advanced liver cancer (hepatocellular carcinoma), a Phase IIb trial for metabolic dysfunction-associated steatohepatitis (MASH), and a Phase IIa study for pancreatic cancer. Additionally, CF602 is in pre-clinical development for erectile dysfunction.

Recent developments in early 2026 include positive Phase 2a data for Namodenoson in pancreatic cancer, with 35% of patients remaining on therapy. The company also reported its 2025 financial results and ongoing clinical progress in March 2026, highlighting a patient with decompensated liver cirrhosis successfully undergoing liver transplantation after Namodenoson treatment. Leadership includes Motti Farbstein as CEO, CFO, and COO, and Dr. Pnina Fishman as the Scientific Founder and Executive Chairman of the Board.